Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 8.9% in March

growth of 12.4% from the February 28th total of 162,500 shares. Based on an average daily volume of 153,200 shares, the short-interest ratio is presently 1.2 days. The number of shares shorted increased 12.4% in the month of March.

( ) saw a significant increase in short interest during the month of march. On March 31, there were 183,100 short shares. This is an increase of 8.9% compared to the total of 168.100 shares on March 15. The days-to-cover is currently 1.8 days based on a daily average volume of 104 200 shares. About 0.3% of the stock is sold short.

Cardiol Therapeutics Stocks Up 12.3 %

On Friday, the stock rose $0.07 to $0.64. Stock of the company traded 284,832 shares versus its average of 105190. The fifty-day moving price of the firm is $0.52, and its 200 day moving price is $0.59. Cardiol Therapeutics' 52-week low is $0.45, and its 52-week high is $1.74. Recently, several institutional investors and hedge fund managers have changed their positions in the company. Royal Bank of Canada increased its holdings in Cardiol Therapeutics shares by 66.2% during the first quarter. Royal Bank of Canada owns 35 214 shares of stock worth $54,000, after buying an additional 14,020 during the period. Advisor Group Holdings Inc. increased its holdings in Cardiol Therapeutics shares by 227.1% during the fourth quarter. Advisor Group Holdings Inc. owns now 74,710 of the company stock valued at $35,000. This is after buying an additional 51 870 shares. Jane Street Group LLC purchased shares of Cardiol Therapeutics valued at $32,000 in the fourth quarter. Vident Investment Advisory LLC increased its stake in Cardiol Therapeutics shares by 139.6% during the first quarter. Vident Investment Advisory LLC owns 126157 shares worth $195,000, after buying an additional 73512 shares. Bank of Montreal Can increased its holdings in Cardiol Therapeutics shares by 5110% during the fourth quarter. Bank of Montreal Can owns 90 000 shares of stock in the company valued at $61,000, after buying an additional 75 269 shares over the period. Institutional investors and hedge fund currently own 7.46%.

Cardiol Therapeutics Company profile

Get Rating

Cardiol Therapeutics, Inc. is a life science company in the clinical stage that focuses on research and clinical trials of anti-inflammatory, anti-fibrotic and other therapies to treat heart disease. CardiolRx is its lead product candidate. It is an oral cannabidiol preparation that is manufactured by pharmaceutical companies and is currently being developed clinically for heart disease. offers a FREE daily email newsletter